It has always been assumed that damaged nerves never regenerate but this may be changing fast. The U.S. Patent and Trademark Office  has issued  two new patents to a regenerative medicine company, NervGen Pharma Corp, dedicated to creating nerve damage treatment solutions.

NervGen’s advances may someday help the 85,556 people with spinal cord injury in Canada.  There are about 4,529 new cases of spinal cord injury in Canada each year. In the United States, an estimated 282,000 people are living with spinal cord injuries, and each year 17,000 Americans suffer a spinal cord injury.

The patents will protect the development and commercialization of protein tyrosine phosphatase sigma targeted therapies for heart diseases and injury, and for root avulsion involving injuries into the peripheral nerve system.

“The issuance of these patents strengthens our intellectual property estate by expanding protections to various diseases and medical conditions where our technology has demonstrated strong preclinical efficacy,” said Dr. Ernest Wong, President& CEO of NervGen.

“We continue to aggressively prosecute the patent portfolio acquired through our 2018 license with Case Western Reserve University as we continue to build evidence for the potential of NVG-291 therapy to positively impact various conditions in addition to spinal cord injury.”

The company’s patented technology was developed in the laboratory of Dr. Jerry Silver, an SCI and regenerative medicine researcher and professor at Cleveland based Case Western Reserve University.

“The discoveries from Dr. Jerry Silver’s laboratory represent significant advancements in nerve regeneration and therapy for nerve damage,” said Bill Radvak. “We are delighted to move NVG-291 and the technology forward, and to work toward bringing Dr. Silver and his team’s revolutionary research to fruition.”